To include your compound in the COVID-19 Resource Center, submit it here.

Zejula’s label expansion reaches an untapped ovarian cancer population

The label expansion for GlaxoSmithKline’s Zejula niraparib will allow the company to tap into a broad ovarian cancer patient population that hasn’t been touched by other PARP inhibitors. It also sends another signal to drugmakers that cancer is still a priority for FDA during the COVID-19 pandemic.

FDA approved an sNDA for Zejula for first-line maintenance treatment of platinum-sensitive ovarian cancer, expanding its label from

Read the full 653 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE